In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids with Eric A. Adams, InMed’s CEO, and Alexandra Mancini, senior VP of clinical and regulatory affairs. The discussion also includes the recent FDA public hearing on cannabidiol (CBD) and its implications for the sector.
InMed’s cannabinol (CBN) formulation for glaucoma – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to
May 27, 2020
